We also evaluated the impact of G‐CSF administration on grades II–IV acute GVHD, overall chronic GVHD, neutrophil recovery, relapse, and OS stratified by recipient age, cytogenetic risk, disease status, conditioning regimen, and GVHD prophylaxis for each donor type. Here, CSF3 is linked to chronic graft versus host disease.